Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

D. Hong, A. Shergill, L. Bazhenova, B. C. Cho, R. Heist, V. Moreno, G. S. Falchook, M. Nagasaka, P. Cassier, B. Besse, D. W. Kim, S. Yoon, X. Le, T. Zhao, S. Atwal, E. Park, J. Lee

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)S72
JournalEuropean Journal of Cancer
StatePublished - Oct 2022
Externally publishedYes

Cite this